中国再生医学(08158)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

08158 中国再生医学

未开盘 10-12 09:20:32

0.310

+0.000

0.00%

最高0.310	最低0.310	成交量0.00
今开0.310	昨收0.310	日振幅0.00%
总市值9,424万	流通市值9,424万	总股本3.04亿
成交额0.00	换手率0.00%	流通股本3.04亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"08158","market":"HK","secType":"STK","nameCN":"中国再生医学","latestPrice":0.31,"timestamp":1791768032395,"preClose":0.31,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":304000000,"shares":304000000,"eps":0.0905,"marketStatus":"未开盘","change":0,"latestTime":"10-12 09:20:32","open":0.31,"high":0.31,"low":0.31,"amount":0,"amplitude":0,"askPrice":0.35,"askSize":15000,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":0.0905,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791855000000},"marketStatusCode":0,"adr":0,"listingDate":995385600000,"exchange":"SEHK","adjPreClose":0.31,"openAndCloseTimeList":[[1791768600000,1791777600000],[1791781200000,1791792000000]],"volumeRatio":0,"lotSize":5000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/08158","defaultTab":"news","newsList":[{"id":"1195440975","title":"中国再生医学2026年9月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1195440975","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195440975?lang=zh_cn&edition=full","pubTime":"2026-10-06 10:20","pubTimestamp":1791253256,"startTime":"0","endTime":"0","summary":"中国再生医学国际有限公司于2026年10月6日披露截至2026年9月30日的证券变动月报显示，公司在报告期内未发生新增股份发行或回购等变动，股本总额保持不变。根据公告，截至9月末，公司法定注册股本数目为5,000,000,000股普通股，每股面值0.20港元，总金额维持在10亿港元，与上月底无差异。已发行股份数目同样保持在304,252,480股，且当月并无库藏股份的增减变动。本次公告由公司秘书陈乐彤签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112405182","title":"中国再生医学2026年中期营收4,173.40万港元，经调整净利润462.30万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1112405182","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112405182?lang=zh_cn&edition=full","pubTime":"2026-09-17 17:04","pubTimestamp":1789635886,"startTime":"0","endTime":"0","summary":"中国再生医学披露的2026年中期财报显示，报告期内，公司实现营收约4,173.40万港元，同比增长52.35%。经调整净利润为462.30万港元，相较上年同期微幅增长0.30%。期内销售成本约1,741.80万港元，同比增幅83.24%，主要系收入规模提升带动成本增加。公司整体毛利率约为58.23%。销售及分销费用约275.20万港元，行政及其他费用合计约1,737.20万港元，两项费用合计推动本期总营运开支达2,012.40万港元，较上年同期增长14.38%。经营活动所用现金净额约394.40万港元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"中国再生医学2026年中期营收4,173.40万港元，经调整净利润462.30万港元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134985594","title":"中国再生医学8月股份变动月报表发布，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1134985594","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134985594?lang=zh_cn&edition=full","pubTime":"2026-09-02 16:01","pubTimestamp":1788336110,"startTime":"0","endTime":"0","summary":"中国再生医学于2026年9月2日发布截至2026年8月31日的股份变动月报表。公司公告显示，报告期内，法定股本依旧为5,000,000,000股普通股，每股面值0.20港元，注册股本总额维持在10亿港元。期末已发行股份数量为304,252,480股，与月初保持一致，公司并无持有库存股份，未发生任何新增发行、购回或注销等变动。公司在公告中表示，本次所有股份及库藏股事务均符合香港联合交易所有限公司《上市规则》和相关法律法规的要求。该公告由公司秘书陈乐彤签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661267898","title":"中国再生医学(08158)公布中期业绩 收益4173.4万港元 同比增长52.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661267898","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661267898?lang=zh_cn&edition=full","pubTime":"2026-08-21 19:08","pubTimestamp":1787310480,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国再生医学(08158)公布2026年中期业绩，收益4173.4万港元，同比增长52.36%;净利462.3万港元，同比基本持平;每股盈利1.51港仙。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1483492.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国再生医学(08158)公布中期业绩 收益4173.4万港元 同比增长52.36%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","08158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173624077","title":"中国再生医学（08158）发布2026年中期业绩：收入增52%至4,173.4万港元 净利4.62百万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1173624077","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173624077?lang=zh_cn&edition=full","pubTime":"2026-08-21 18:42","pubTimestamp":1787308927,"startTime":"0","endTime":"0","summary":"2026年8月21日，中国再生医学国际有限公司披露截至2026年6月30日止六个月未经审核中期业绩。期内，公司收入41,734,000港元，较2025年同期的27,391,000港元增长52.35%。毛利24,316,000港元，同比增加36.02%。公司实现除税前溢利4,623,000港元，与去年同期的4,609,000港元基本持平；归属公司权益持有人溢利同为4,623,000港元。区域上，香港市场收入38,506,000港元，占比92.21%；中国内地收入3,228,000港元。公司指出，期内受惠于中国内地访港消费拉动业务增长，但本地消费意欲减弱及经营成本上升影响整体表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153928600","title":"中国再生医学国际（08158）将于8月21日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1153928600","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153928600?lang=zh_cn&edition=full","pubTime":"2026-08-11 16:40","pubTimestamp":1786437658,"startTime":"0","endTime":"0","summary":"中国再生医学国际有限公司（08158）8月11日公告，公司董事会已订于2026年8月21日（星期五）召开会议，主要议程包括：  \n1. 审议及批准公司及其附属公司截至2026年6月30日止六个月的未经审核综合中期业绩；  \n2. 审议中期业绩公告的刊发；  \n3. 讨论及考虑派付股息（如有）。\n公告显示，董事会由执行董事王闯（主席兼行政总裁）、非执行董事雒敏，以及独立非执行董事霍春玉、周旭东、梁文辉组成。\n根据公告，该文件将自刊发之日起至少七日内登载于香港交易所网站（www.hkexnews.hk）的“最新上市公司公告”栏目及公司网站（www.crmi.hk）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143929980","title":"中国再生医学7月股份变动月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1143929980","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143929980?lang=zh_cn&edition=full","pubTime":"2026-08-04 12:35","pubTimestamp":1785818138,"startTime":"0","endTime":"0","summary":"中国再生医学国际有限公司于2026年8月4日发布2026年7月股份变动月报表。报告显示，截至2026年7月31日，公司注册股本维持5,000,000,000股普通股，面值每股0.2港元，注册股本合计10亿港元，较上月底无新增或减少。本月内无新增发行及回购或注销活动，现有股本数量维持稳定。公司表示，已遵守香港联合交易所有限公司的相关上市规则及法律规定，并已完成所有必要的审批和存档程序。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197192143","title":"中国再生医学2026年6月股份变动月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1197192143","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197192143?lang=zh_cn&edition=full","pubTime":"2026-07-03 12:24","pubTimestamp":1783052647,"startTime":"0","endTime":"0","summary":"中国再生医学于2026年7月3日发布了截至2026年6月30日的股份变动月报表。公告显示，公司本月无新增发行、回购或注销活动，股本结构未发生变化。公告指出，截至本月末，公司法定/注册股本仍为50亿股，面值每股0.2港元，总额10亿港元，与上月保持一致。公司在公告中确认，股份发行及期权计划事宜均符合香港联交所《GEM上市规则》和相关法律法规要求，公告由公司秘书陈乐彤签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102007519","title":"中国再生医学：2015年新购股权计划获正式采纳，限额达30,425,248份","url":"https://stock-news.laohu8.com/highlight/detail?id=1102007519","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102007519?lang=zh_cn&edition=full","pubTime":"2026-06-12 17:35","pubTimestamp":1781256916,"startTime":"0","endTime":"0","summary":"在截至2015年12月31日的年度内，中国再生医学于当年6月27日正式采纳新购股权计划，适用期限覆盖至2015年年底。根据公告，该计划当年可授出的购股权数目为30,425,248份，另在“服务提供商分项限额”下可另行授出3,042,524份。公司同时指出，此次补充公告所披露的内容并不影响2015年年报中其他已公布的事项。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国再生医学：2015年新购股权计划获正式采纳，限额达30,425,248份","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170335622","title":"中国再生医学5月股份变动月报表：公司股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1170335622","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170335622?lang=zh_cn&edition=full","pubTime":"2026-06-03 11:01","pubTimestamp":1780455719,"startTime":"0","endTime":"0","summary":"中国再生医学于2026年6月3日发布2026年5月股份变动月报表。本次月报所披露的报告期为2026年5月1日至5月31日。本月内公司并未进行任何新的股份发行、购回、注销或库藏股变动，股本结构保持稳定。受该期权计划行使所产生的新股及库藏股份本月均未有实际变动，同时公司确认遵守香港联交所《上市规则》及相关法律法规。公告由公司秘书陈乐彤签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114148276","title":"中国再生医学(08158)拟回购最多10%已发行股本","url":"https://stock-news.laohu8.com/highlight/detail?id=1114148276","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114148276?lang=zh_cn&edition=full","pubTime":"2026-06-02 19:06","pubTimestamp":1780398393,"startTime":"0","endTime":"0","summary":"中国再生医学，于香港联交所GEM上市，正计划在2026年6月26日举行股东周年大会上寻求股东授予一般性授权，以回购不超过其已发行股份总数10%的股份。董事会指出，按2026年5月28日已发行的约3.04亿股计算，拟回购上限约为3042.52万股。根据公告，此次回购的资金将来自公司的可分配溢利或发行股份所得等合法来源，并遵循开曼群岛公司法及GEM上市规则。此次回购计划最终实施尚需股东大会批准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国再生医学(08158)拟回购最多10%已发行股本","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168498276","title":"中国再生医学公布4月股份变动月报，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1168498276","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168498276?lang=zh_cn&edition=full","pubTime":"2026-05-04 19:26","pubTimestamp":1777893997,"startTime":"0","endTime":"0","summary":"中国再生医学于2026年5月4日发布2026年4月股份变动月报表。公告显示，公司本月底法定注册股本维持在50亿股，每股面值为0.2港元，注册股本总额为10亿港元，与上月底保持一致。报告期末，公司已发行股份总数为304,252,480股，库存股份数目为零，较上月底均无变化。公司表示，所有本月涉及的证券发行或库藏股相关事务，已获得董事会正式授权并严格遵守联交所《上市规则》和相关法律法规的规定。本次月报由公司秘书陈乐彤签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182948386","title":"中国再生医学(08158)聚焦跨境医疗服务 年度净利同比大增55%","url":"https://stock-news.laohu8.com/highlight/detail?id=1182948386","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182948386?lang=zh_cn&edition=full","pubTime":"2026-04-28 17:41","pubTimestamp":1777369274,"startTime":"0","endTime":"0","summary":"2025年度，中国再生医学在跨境医疗需求回升及成本管控等多重举措下，实现收入约72,060,000港元，同比下降约20.48%，但年度溢利约27,530,000港元，相比2024年度的17,750,000港元上升约55%。毛利约41,920,000港元，与收入走势同步同比减少27.29%。展望后续经营，集团将继续围绕跨境医疗、美容与健康服务的协同拓展，结合香港与内地市场的合作机遇，强化核心竞争力并稳步推进资源配置与业务升级。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国再生医学(08158)聚焦跨境医疗服务 年度净利同比大增55%","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513779848","title":"中国再生医学盘中异动 早盘股价大跌9.43%报0.240港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513779848","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513779848?lang=zh_cn&edition=full","pubTime":"2025-02-24 09:59","pubTimestamp":1740362393,"startTime":"0","endTime":"0","summary":"2025年02月24日早盘09时59分，中国再生医学股票出现波动，股价大幅跳水9.43%。截至发稿，该股报0.240港元/股，成交量10000股，换手率0.00%，振幅0.00%。资金方面，该股资金流入0港元，流出2400港元。中国再生医学股票所在的医疗及医学美容服务行业中，整体跌幅为0.05%。其相关个股中，瑞丽医美、固生堂、医脉通涨幅较大，振幅较大的相关个股有健康之路、讯飞医疗科技、固生堂，振幅分别为27.09%、17.29%、7.18%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224095953962dd746&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224095953962dd746&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","08158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509767832","title":"中国再生医学(08158)股价上升7.843%，现价港币$0.275","url":"https://stock-news.laohu8.com/highlight/detail?id=2509767832","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509767832?lang=zh_cn&edition=full","pubTime":"2025-02-07 14:50","pubTimestamp":1738911000,"startTime":"0","endTime":"0","summary":"[上升股]中国再生医学(08158) 股价在下午02:50比前收市价上升7.843%，现股价为港币$0.275。至目前为止，今日最高价为$0.275，而最低价为$0.275。总成交量为1.5万股，总成交金额为港币$4125。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2502074545/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2502074545/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","08158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509341756","title":"中国再生医学盘中异动 早盘股价大涨5.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509341756","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509341756?lang=zh_cn&edition=full","pubTime":"2025-02-07 10:33","pubTimestamp":1738895582,"startTime":"0","endTime":"0","summary":"2025年02月07日早盘10时33分，中国再生医学股票出现异动，股价急速上涨5.88%。中国再生医学股票所在的医疗及医学美容服务行业中，整体涨幅为0.48%。其相关个股中，万嘉集团、中国再生医学、讯飞医疗科技涨幅较大，振幅较大的相关个股有万嘉集团、健康之路、瑞尔集团，振幅分别为9.09%、7.47%、7.19%。中国再生医学公司简介：本公司为投资控股公司,其附属公司的主要业务为提供医美服务及保健产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207103302961a9eee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207103302961a9eee&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","08158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509121762","title":"中国再生医学盘中异动 大幅跳水7.02%报0.265港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509121762","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509121762?lang=zh_cn&edition=full","pubTime":"2025-02-06 14:51","pubTimestamp":1738824673,"startTime":"0","endTime":"0","summary":"2025年02月06日下午盘14时51分，中国再生医学股票出现异动，股价快速跳水7.02%。截至发稿，该股报0.265港元/股，成交量10000股，换手率0.00%，振幅7.02%。资金方面，该股资金流入0港元，流出2750港元。中国再生医学股票所在的医疗及医学美容服务行业中，整体涨幅为0.59%。其相关个股中，时代天使、卓珈控股、医渡科技涨幅较大，振幅较大的相关个股有一脉阳光、医脉通、雍禾医疗，振幅分别为11.51%、8.65%、7.95%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502061451139619c2e5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502061451139619c2e5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","08158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2505304000","title":"中国再生医学盘中异动 股价大跌6.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505304000","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2505304000?lang=zh_cn&edition=full","pubTime":"2025-01-24 13:41","pubTimestamp":1737697269,"startTime":"0","endTime":"0","summary":"2025年01月24日下午盘13时41分，中国再生医学股票出现异动，股价大幅跳水6.56%。中国再生医学股票所在的医疗及医学美容服务行业中，整体跌幅为0.04%。其相关个股中，中国生物科技服务、医渡科技、万嘉集团涨幅较大，振幅较大的相关个股有中国生物科技服务、医渡科技、艾迪康控股，振幅分别为13.04%、10.72%、9.27%。中国再生医学公司简介：本公司为投资控股公司,其附属公司的主要业务为提供医美服务及保健产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250124134109a22dc733&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250124134109a22dc733&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","08158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2501297084","title":"中国再生医学公布金道连城获委任为新任核数师","url":"https://stock-news.laohu8.com/highlight/detail?id=2501297084","media":"新浪港股","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2501297084?lang=zh_cn&edition=full","pubTime":"2025-01-07 08:30","pubTimestamp":1736209800,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　中国再生医学（08158）发布公告，于2025年1月6日，中正天恒会计师有限公司向董事会递交辞呈函，辞任公司核数师一职，即时生效。\n　　在审核委员会的推荐建议下，金道连城会计师事务所有限公司自2025年1月6日起获委任为公司新任核数师，以填补中正天恒辞任后之临时空缺，任期至公司下届股东周年大会结束时为止。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-01-07/doc-ineeayzc2381492.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","08158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2501258072","title":"中国再生医学(08158)：金道连城获委任为新任核数师","url":"https://stock-news.laohu8.com/highlight/detail?id=2501258072","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2501258072?lang=zh_cn&edition=full","pubTime":"2025-01-06 22:44","pubTimestamp":1736174673,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国再生医学(08158)发布公告，于2025年1月6日，中正天恒会计师有限公司向董事会递交辞呈函，辞任公司核数师一职，即时生效。在审核委员会的推荐建议下，金道连城会计师事务所有限公司自2025年1月6日起获委任为公司新任核数师，以填补中正天恒辞任后之临时空缺，任期至公司下届股东周年大会结束时为止。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1234085.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","08158"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.crmi.hk","stockEarnings":[{"period":"1week","weight":-0.0159},{"period":"1month","weight":0.7127},{"period":"3month","weight":0.1071},{"period":"6month","weight":-0.0313},{"period":"1year","weight":-0.5156},{"period":"ytd","weight":-0.2619}],"compareEarnings":[{"period":"1week","weight":0.0096},{"period":"1month","weight":-0.0215},{"period":"3month","weight":-0.0029},{"period":"6month","weight":-0.0646},{"period":"1year","weight":-0.0768},{"period":"ytd","weight":-0.053}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中国再生医学国际有限公司是一家主要从事提供大健康产品及服务的投资控股公司。该公司从事提供并销售医疗产品及医疗仪器。此外，该公司提供健康状况评估、排毒疗程、体内平衡、养护器官及增强免疫系统等多种健康管理等服务。","yearOnYearQuotes":[{"month":1,"riseRate":0.24,"avgChangeRate":-0.049446},{"month":2,"riseRate":0.6,"avgChangeRate":0.22676},{"month":3,"riseRate":0.36,"avgChangeRate":-0.019341},{"month":4,"riseRate":0.56,"avgChangeRate":0.136675},{"month":5,"riseRate":0.32,"avgChangeRate":-0.037505},{"month":6,"riseRate":0.32,"avgChangeRate":-0.05408},{"month":7,"riseRate":0.24,"avgChangeRate":0.014296},{"month":8,"riseRate":0.230769,"avgChangeRate":-0.035882},{"month":9,"riseRate":0.307692,"avgChangeRate":-0.080444},{"month":10,"riseRate":0.538462,"avgChangeRate":0.113012},{"month":11,"riseRate":0.48,"avgChangeRate":0.113058},{"month":12,"riseRate":0.36,"avgChangeRate":-0.031515}],"exchange":"SEHK","name":"中国再生医学","nameEN":"CRMI"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国再生医学(08158)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国再生医学(08158)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国再生医学,08158,中国再生医学股票,中国再生医学股票老虎,中国再生医学股票老虎国际,中国再生医学行情,中国再生医学股票行情,中国再生医学股价,中国再生医学股市,中国再生医学股票价格,中国再生医学股票交易,中国再生医学股票购买,中国再生医学股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国再生医学(08158)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国再生医学(08158)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}